• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
CONCLUSIONS: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. TRIAL REGISTRATION: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049. PMID: 31665733 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - October 29, 2019 Category: Urology & Nephrology Authors: Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B, FIGARO-DKD study investigators Tags: Am J Nephrol Source Type: research

Effect of Chronic Kidney Disease on Cardiovascular Events: An Epidemiological Aspect from SPRINT Trial.
CONCLUSIONS: SPRINT is the first trial revealing that CKD is an independent risk factor for CVD. However, CKD could not be considered as a CVD risk equivalent. In the presence of CKD, with intensive blood pressure reduction the chance of AKI is dramatically increased. PMID: 31705750 [PubMed - in process]
Source: Iranian Journal of Kidney Diseases - November 12, 2019 Category: Urology & Nephrology Tags: Iran J Kidney Dis Source Type: research

Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study
ConclusionsHigher MPO level was associated with increased risk for CKD progression, but not with CVD and death in patients with CKD from CRIC. Whether therapies aimed at reducing MPO activity can result in improved clinical outcomes is yet to be determined.
Source: American Journal of Kidney Diseases - December 20, 2019 Category: Urology & Nephrology Source Type: research

The association between CHA2DS2-VASc score and erectile dysfunction: a cross-sectional study
Conclusion: CHA2DS2-VASc score can be used to detect Erectile dysfunction in patients who are admitted to the cardiology outpatient clinics.
Source: International Braz J Urol - December 20, 2019 Category: Urology & Nephrology Source Type: research

Selected cardiovascular risk factors in early stages of chronic kidney disease
AbstractCardiovascular diseases, including hypertension, congestive heart failure, myocardial infarction, stroke and atherosclerosis, are common in patients with chronic kidney disease. Aside from the standard biomarkers, measured to determine cardiovascular risk, new ones have emerged: markers of oxidative stress, apoptosis, inflammation, vascular endothelium dysfunction, atherosclerosis, organ calcification and fibrosis. Unfortunately, their utility for routine clinical application remains to be elucidated. A causal relationship between new markers and cardiovascular diseases in patients with chronic kidney disease remai...
Source: International Urology and Nephrology - January 17, 2020 Category: Urology & Nephrology Source Type: research

Association of trimethylamine N-Oxide with cardiovascular and all-cause mortality in hemodialysis patients.
CONCLUSIONS: High plasma TMAO level is significantly and independently associated with cardiovascular and all-cause mortality in HD patients. PMID: 32985309 [PubMed - in process]
Source: Renal Failure - September 29, 2020 Category: Urology & Nephrology Tags: Ren Fail Source Type: research

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
Conclusion: SGLT2 inhibitors are novel antidiabetic medications with immense utility in the management of patients with T2DM. Furthermore, SGLT2 inhibitors have demonstrated to reduce the progression to advanced forms of kidney disease and its associated complications. These medications should be front and center in the management of patients with diabetic kidney disease with and without chronic kidney disease as they confer protection against cardiovascular/renal death and improve all-cause mortality. Future studies should evaluate the benefits and implications of early initiation of SGLT2 inhibitors, as well as the long-...
Source: International Journal of Nephrology and Renovascular Disease - November 7, 2020 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research

The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review
ConclusionsRoxadustat has higher mean Hb level than placebo or EPO. Due to the short follow-up period and the lack of critical data, more RCTs are needed to prove long-term safety and effectiveness of roxadustat in the future.
Source: International Urology and Nephrology - January 3, 2021 Category: Urology & Nephrology Source Type: research

Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present
Am J Nephrol. 2021 Apr 15:1-8. doi: 10.1159/000515622. Online ahead of print.ABSTRACTBACKGROUND: A full understanding of the mechanisms of action of aldosterone and its interaction with the mineralocorticoid receptor (MR) allows a theoretical framework to predict the therapeutic potential of MR antagonists (MRAs) in CKD, and heart failure with reduced ejection fraction.SUMMARY: The initial focus on the mechanisms of action of aldosterone was directed primarily on its role in modulating renal excretory function. In contrast, many recent studies have demonstrated a wider and expanded role for aldosterone in modulating inflam...
Source: American Journal of Nephrology - April 15, 2021 Category: Urology & Nephrology Authors: Murray Epstein Source Type: research

Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain
CONCLUSIONS: In Spain, CKD population is older and comorbidities, including diabetes and heart failure, are common. Cardiovascular and renal outcomes are frequent. There is room for improvement in CKD management, particularly through the use of drugs with proven cardiovascular and renal benefit.PMID:34148667 | DOI:10.1016/j.nefro.2021.03.006
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - June 21, 2021 Category: Urology & Nephrology Authors: Carlos Escobar Unai Aranda Beatriz Palacios Margarita Capel Antoni Sicras Aram Sicras Antonio Hormigo Roberto Alc ázar Nicol ás Manito Manuel Botana Source Type: research

Pages: 1  2  3  4  5  6  7  8  9